A Restrospective Study of Secondary Malignancies in Myelofibrosis Patients Receiving Ruxolitinib Therapy Myelofibrosis (MF) is a chronic, rare, and often fatal type of blood cancer characterized by a progressive replacement of bone marrow with fibrous scar tissue. This type of myeloproliferative neoplasm (MPN) leads to progressive spleen enlargement, systemic symptoms such